about
Hypersensitivity associated with sugammadex administration: a systematic reviewAn in vivo strategy to counteract post-administration anticoagulant activity of azido-Warfarin.Sugammadex: A revolutionary drug in neuromuscular pharmacologyAn overview of clinical research for anesthesiologists.Effect of Sugammadex on Postoperative Bleeding and Coagulation Parameters After Septoplasty: A Randomized Prospective Study.A discrete event simulation model of clinical and operating room efficiency outcomes of sugammadex versus neostigmine for neuromuscular block reversal in CanadaSugammadex and ideal body weight in bariatric surgery.Sugammadex, a neuromuscular blockade reversal agent, causes neuronal apoptosis in primary cultures.Neuronal Effects of Sugammadex in combination with Rocuronium or Vecuronium.Anesthetizing the obese child.Cucurbit[n]uril type hosts for the reversal of steroidal neuromuscular blocking agents.Inhibitors of acetylcholinesterase and butyrylcholinesterase meet immunity.Reversing neuromuscular blockade: inhibitors of the acetylcholinesterase versus the encapsulating agents sugammadex and calabadion.Current evidence for the use of sugammadex in children.Comparison of reversal and adverse effects of sugammadex and combination of - Anticholinergic-Anticholinesterase agents in pediatric patients.Profile of sugammadex for reversal of neuromuscular blockade in the elderly: current perspectives.Elderly Patients Require Higher Doses of Sugammadex for Rapid Recovery from Deep Neuromuscular Block.Comparison of effects of sugammadex and neostigmine on QTc prolongation in rabbits under general anesthesia.Effect of Low and High Dose Sugammadex on the Coagulation and Fibrinolytic System in Rats
P2860
Thirty-Day Postoperative Outcomes Following Sugammadex Use in Colorectal Surgery Patients; Retrospective StudyThe effect of magnesium on the reversal of rocuronium-induced neuromuscular block with sugammadex: an ex vivo laboratory studySugammadex for Reversal of Neuromuscular Blockade in a Patient With Renal FailureAnaphylaxis Induced by Sugammadex in a Patient with Papillary Serous Carcinoma of the Uterine Adnexa Undergoing Exploratory LaparotomyCrowdsourcing sugammadex adverse event rates using an in-app survey: feasibility assessment from an observational study
P921
Q26823864-61922A4A-822E-4C0C-A929-3EE528E42338Q33754113-B2238B50-E47E-42C5-B317-4E2594D70CACQ34236933-6B646DE5-A830-43A5-A6B2-F08D409219C9Q34921143-E9962D52-9E37-49BD-9441-CD5F335C1838Q35965686-B5ED751F-3C1E-4135-986D-5112F8331F19Q36194432-01605AA6-87A8-428C-B608-12BF6EB14F76Q36948458-1DF25B9B-1559-4C8D-9F90-26CA445122A0Q37119299-CA925B05-ED09-405D-BFA7-416A4A372F81Q37725911-3EDBBCD6-187E-449C-BE51-0833E91F94E7Q37856443-04C241CC-C100-47D1-B92A-A3FA3D1F8789Q38161549-24CE152A-2510-45DD-B048-05794DC3D48BQ38217301-B5752503-9B03-4B1C-9DCA-3CD284CE3D17Q38707992-A84FC0F4-75C9-49D5-B5DE-F1B5E1DE0C89Q39012385-AC23585C-E1EC-41BD-BEEB-81C6FF43DF7BQ43010324-3491AF2D-5D44-4299-84A9-FBFE226E2A24Q47213588-5799BE6B-AC12-4AB9-BEF9-870B626A76F8Q47634540-560DF832-1F13-4A55-BE97-7E35BEC9328AQ47773137-DDA54657-EB52-41EE-BD8E-3270D1FE9BEDQ59104207-202FA298-1265-4839-8D90-BD4FA65EC934
P2860
description
2009 nî lūn-bûn
@nan
2009 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Sugammadex
@ast
Sugammadex
@en
type
label
Sugammadex
@ast
Sugammadex
@en
prefLabel
Sugammadex
@ast
Sugammadex
@en
P1433
P1476
Sugammadex
@en
P2093
Lily P.H. Yang
Susan J. Keam
P304
P356
10.2165/00003495-200969070-00008
P577
2009-05-01T00:00:00Z
P5875
P6179
1028465269